Search

Learn how a mentoring program at Memorial Sloan Kettering Cancer Center helped two nurses excel in their roles.

… Monday, August 23, 2021 Some nurses administer lifesaving treatments. Some conduct research. Some educate the next generation of nurses. And that’s just scratching the surface. At their core, nurses want to help others, whether that means patients and families or their own colleagues. Recognizing that

Memorial Sloan Kettering has named three winners of this year’s Paul Marks Prize for Cancer Research, an award that recognizes promising early-career investigators.

… Friday, December 1, 2017 Paul Marks prize medal The prize medal features an image of Paul Marks, who led MSK for nearly two decades. MSK President and CEO Craig Thompson MSK President and CEO Craig Thompson presented the honorees with their medals and award checks during a luncheon held before the symposium

For the first time, our annual seminar for high school students and teachers from the New York City area will be available to watch live from around the nation and the world.

… Tuesday, November 6, 2012 Summary For the first time, our annual seminar for high school students and teachers from the New York City area will be available to watch live from around the nation and the world. For the first time, our annual Major Trends in Modern Cancer Research seminar for high school

Learn about former MSK postdoctoral scientist Cornelius Taabazuing, who now leads his own laboratory at University of Pennsylvania.

… Wednesday, September 25, 2024 Cornelius Taabazuing, PhD, cuts right to the chase when asked what advice he would give someone considering whether to join Memorial Sloan Kettering Cancer Center (MSK) as a postdoctoral researcher. “It’s a no-brainer,” he says with a laugh. “You work with brilliant people

Memorial Sloan Kettering Cancer Center (MSK) announced today that Ross Levine, MD, has been named MSK’s new Chief Scientific Officer (CSO). A renowned physician-scientist, Dr. Levine previously served as Senior Vice President of Translational Research in Memorial Hospital (MH) and holds the Edward P. Evans Endowed Chair for Myelodysplastic Syndromes at MSK.

… Thursday, October 16, 2025 Memorial Sloan Kettering Cancer Center (MSK) announced today that Ross Levine, MD , has been named MSK’s new Chief Scientific Officer (CSO). A renowned physician-scientist, Dr. Levine previously served as Senior Vice President of Translational Research in Memorial Hospital

In response to the intense fear that so many people experience around imaging tests, MSK radiology nurses developed new recommendations that are helping patients everywhere.

… Thursday, September 11, 2025 The cancer may be gone, but for many patients the medical tests continue, and so do the fear and worry.  Now, a group of radiology nurses at Memorial Sloan Kettering Cancer Center (MSK) say it’s time to bring awareness — and relief — to the countless patients and their caregivers

Learn how people with cancer can reduce insomnia during and after treatment.

… Thursday, March 15, 2018 Summary Many people with cancer suffer from insomnia, both during treatment and sometimes for years after. Effective insomnia treatments exist, including a special type of cognitive behavioral therapy. There are also relaxation techniques, acupuncture, and medication. Insomnia

A team of experts at Memorial Sloan Kettering shared their insights on colorectal cancer and general digestive health in an Information Session for patients, caregivers and those at increased risk for the disease.

… Thursday, June 25, 2020 A team of experts at Memorial Sloan Kettering shared their insights on colorectal cancer and general digestive health in an Information Session for patients, caregivers and those at increased risk for the disease.   Members of the MSK community joined the session to have their

Two new therapy options have demonstrated significant advances in survival outcomes for select patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Both studies were presented today at the 2025 ASCO Annual Meeting in Chicago and simultaneously published in The New England Journal of Medicine.

… Saturday, May 31, 2025 Two new therapy options have demonstrated significant advances in survival outcomes for select patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Both studies were presented today at the 2025 ASCO Annual

New MSK research identifies a rare cell population responsible for AML persistence and resistance to therapy; sheds new light on early brain development; and investigates how other health conditions can increase cancer risk in midlife. MSK clinical trials also supported the recent approval of the targeted drug larotrectinib by the FDA.

… Wednesday, April 23, 2025 New research from Memorial Sloan Kettering Cancer Center (MSK) identifies a rare cell population responsible for AML persistence and resistance to therapy; sheds new light on early brain development; and investigates how other health conditions can increase cancer risk in midlife